This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Is Humana (HUM) Up 0.7% Since Last Earnings Report?
by Zacks Equity Research
Humana (HUM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Molina (MOH) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Investors Should Retain Molina Healthcare (MOH) Now
by Zacks Equity Research
Molina Healthcare (MOH) is well-poised for improvement on the back of membership growth in the Medicaid and Medicare businesses. Acquisitions and a solid cash balance act as added tailwinds.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is Molina Healthcare (MOH) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks Industry Outlook Highlights UnitedHealth, The Cigna, Humana, Centene and Molina Healthcare
by Zacks Equity Research
UnitedHealth, The Cigna, Humana, Centene and Molina Healthcare are part of the Zacks Industry Outlook article.
Tenet (THC) to Divest 3 Hospitals to Novant to Reduce Debt
by Zacks Equity Research
Tenet (THC) expects the divestment of the three South Carolina hospitals to fetch around $2.4 billion in cash.
5 HMO Stocks Set to Gain From Growing Membership, Tech Advancements
by Debasmita Chatterjee
Rising premiums, contract wins, a telehealth services suite and the M&A strategy are expected to drive the performances of the Zacks Medical-HMO industry players. UNH, CI, HUM, CNC and MOH are poised to benefit from encouraging industry prospects.
Is Molina (MOH) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
Molina (MOH) could produce exceptional returns because of its solid growth attributes.
Zacks.com featured highlights Modine Manufacturing, Everest Group, Hilton Worldwide and Molina Healthcare
by Zacks Equity Research
Modine Manufacturing, Everest Group, Hilton Worldwide and Molina Healthcare have been highlighted in this Screen of The Week article.
Encompass Health (EHC) Opens Second Hospital in Wisconsin
by Zacks Equity Research
The inpatient rehabilitation hospital's opening in Fitchburg, WI, was moved up from the initially scheduled first quarter of 2024.
Pick These 4 Stocks With Excellent Interest Coverage Ratio
by Sumit Singh
A company that is capable of generating earnings well above its interest expense can withstand financial hardship. MOD, EG, HLT and MOH are sound enough to meet financial obligations.
Molina Healthcare, Inc (MOH) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Molina (MOH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
HCA Healthcare (HCA) Unveils Ambitious 5-Year Growth Targets
by Zacks Equity Research
Over the five-year horizon, HCA Healthcare (HCA) anticipates substantial 8-12% annual growth in earnings per share.
Is Centene (CNC) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Brookdale Senior (BKD) Shares Rise 1.9% Despite Q3 Earnings Miss
by Zacks Equity Research
Brookdale Senior (BKD) expects adjusted EBITDA to be within the $77-$82 million range in the fourth quarter.
Select Medical (SEM) Stock Down 6.6% Despite Q3 Earnings Beat
by Zacks Equity Research
Select Medical (SEM) continues to expect adjusted EBITDA to be between $795 million and $825 million in 2023.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Cigna (CI) Q3 Earnings Beat on Membership Growth, '23 EPS View Up
by Zacks Equity Research
Cigna's (CI) Q3 results benefit on well-performing U.S. Commercial and Medicare Advantage businesses. Management currently expects 2023 adjusted EPS to be a minimum of $24.75.
Humana (HUM) Q3 Earnings Beat on Strong Individual MA Unit
by Zacks Equity Research
Humana (HUM) continues to project 2023 adjusted EPS at a minimum of $28.25, which suggests growth from the 2022 figure of $25.88.
Molina (MOH) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Molina (MOH) possesses solid growth attributes, which could help it handily outperform the market.
Encompass Health's (EHC) Q3 Earnings Beat on Discharge Growth
by Zacks Equity Research
Encompass Health's (EHC) Q3 results benefit from an increase in patient volumes and net patient revenue per discharge. Management currently projects adjusted EPS to be within $3.41-$3.52 for 2023.
Molina Healthcare (MOH) Q3 Earnings Beat on Membership Growth
by Zacks Equity Research
Molina Healthcare's (MOH) third-quarter results gain from changes in the member mix and a growing premium base. Management reiterates its 2023 adjusted EPS guidance to be a minimum of $20.75.
Universal Health (UHS) Q3 Earnings Beat on Adjusted Patient Days
by Zacks Equity Research
Universal Health (UHS) has a leftover repurchase capacity of around $580 million as of Sep 30, 2023.
Here's What Key Metrics Tell Us About Molina (MOH) Q3 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Molina (MOH) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.